Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
39.30-0.08 (-0.20%)
At close: 4:00PM EDT
39.50 +0.20 (+0.51%)
After hours: 04:54PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close39.38
Open39.77
Bid33.00 x 1800
Ask41.00 x 900
Day's Range39.19 - 40.00
52 Week Range22.92 - 44.80
Volume443,116
Avg. Volume426,637
Market Cap3.191B
Beta (5Y Monthly)1.29
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Intra-Cellular Therapies to Host a Virtual Event to Feature Highlights of Several of its Development Programs

    Virtual event to include discussions on our lumateperone, ITI-1284, PDE1 inhibitors and ITI-333 platforms Webcast scheduled for Wednesday, Oct. 20 from 12:30 to 3:30 p.m. ET NEW YORK, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a virtual event to discuss the Company’s robust pipeline includi

  • GlobeNewswire

    Intra-Cellular Therapies Announces Publication of Lumateperone Pivotal Phase 3 Study in Bipolar Depression in The American Journal of Psychiatry

    In this study, lumateperone 42 mg showed significant reduction in depressive symptoms compared to placebo in patients with a major depressive episode associated with bipolar I or bipolar II disorder and a favorable safety and tolerability profile. These anti-depressant effects were statistically significant in both bipolar I and bipolar II disorder subgroup populations Consistent with prior studies, weight changes were similar to placebo with no notable changes in metabolic or prolactin levels.

  • GlobeNewswire

    Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference

    NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 10:40 am ET. The live and archived webcast can be accessed under "Events & Pr

Advertisement
Advertisement